glp-1 agonist pregnancy medications like Ozempic, Wegovy and Mounjaro are changing diabetes and weight management, but they aren't recommended during or while nursing. The current recommendation is to stop before conception and discuss Periconceptional GLP-1 receptor agonist exposure

Abstract Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality

Reports suggest the peptide may enhance fibroblast migration and proliferation, potentially contributing to faster granulation and re-epithelialization

Detoxification after pharmacological treatments

Combination (IGF-1 LR3 + Follistatin-344): +4452% additive rather than synergistic, confirming non-redundant mechanistic pathways